CIP
TEVA icon

Chartwell Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Chartwell Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.89M Hold
105,000
– – 0.06% 293
2024
Q2 		$1.71M Buy
+105,000
New +$1.62M 0.06% 300

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Chartwell Investment Partners's TEVA Position: Q3 2024 in Review

Chartwell Investment Partners held its Teva Pharmaceuticals (TEVA) position steady in Q3 2024 at 105,000 shares worth $1.89M. The position accounts for 0.06% of the portfolio, ranked #293.

Chartwell Investment Partners first reported a position in TEVA in Q2 2024 and has held it in 2 quarters since. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Chartwell Investment Partners held 105,000 shares of Teva Pharmaceuticals worth $1.89M as of Q3 2024.
  • Chartwell Investment Partners left its Teva Pharmaceuticals share count unchanged in Q3 2024.
  • Teva Pharmaceuticals made up 0.06% of Chartwell Investment Partners's portfolio in Q3 2024, its #293 holding.
  • Chartwell Investment Partners first reported a position in Teva Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.